Biosimilars in the management of neutropenia: focus on filgrastim

Désirée Caselli,1 Simone Cesaro,2 Maurizio Aricò1 1Medical Department, Pediatric Unit, Azienda Sanitaria Provinciale Ragusa, Ragusa, 2Department of Pediatrics, Pediatric Hematology Oncology, Azienda Ospedaliera Universitaria Integrata, Verona, Italy Abstract: Advanc...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Caselli D, Cesaro S, Aricò M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	neutropenia filgrastim biosimilars Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/4d89cc2f957e45c99acdc3cadddf2ed7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4d89cc2f957e45c99acdc3cadddf2ed7
record_format	dspace
spelling	oai:doaj.org-article:4d89cc2f957e45c99acdc3cadddf2ed72021-12-02T03:45:15ZBiosimilars in the management of neutropenia: focus on filgrastim1177-5491https://doaj.org/article/4d89cc2f957e45c99acdc3cadddf2ed72016-02-01T00:00:00Zhttps://www.dovepress.com/biosimilars-in-the-management-of-neutropenia-focus-on-filgrastim-peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491Désirée Caselli,1 Simone Cesaro,2 Maurizio Aricò1 1Medical Department, Pediatric Unit, Azienda Sanitaria Provinciale Ragusa, Ragusa, 2Department of Pediatrics, Pediatric Hematology Oncology, Azienda Ospedaliera Universitaria Integrata, Verona, Italy Abstract: Advances in chemotherapy and surgery allows the majority of patients to survive cancer diseases. Yet, the price may be a proportion of patients dying of complications due to treatment-induced infectious complications, such as neutropenia. With the aim of decreasing morbidity and mortality related to infectious complications, recombinant human granulocyte colony-stimulating factor (G-CSF), filgrastim, and pegylated filgrastim have been used to reduce time and degree of neutropenia. A biosimilar is a copy of an approved original biologic medicine whose data protection has expired. The patent for filgrastim expired in Europe in 2006 and in the US in 2013. This review analyses the available evidence to be considered in order to design a strategy of use of G-CSF and its biosimilars. The clinical and safety outcomes of biosimilars are well within the range of historically reported data for originator filgrastim. This underscores the clinical effectiveness and safety of biosimilar filgrastim in daily clinical practice. Biosimilars can play an important role by offering the opportunity to reduce costs, thus contributing to the financial sustainability of treatment programs. Keywords: neutropenia, filgrastim, biosimilars, G-CSF, fever, prophylaxisCaselli DCesaro SAricò MDove Medical PressarticleneutropeniafilgrastimbiosimilarsMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2016, Iss Issue 1, Pp 17-22 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	neutropenia filgrastim biosimilars Medicine (General) R5-920
spellingShingle	neutropenia filgrastim biosimilars Medicine (General) R5-920 Caselli D Cesaro S Aricò M Biosimilars in the management of neutropenia: focus on filgrastim
description	Désirée Caselli,1 Simone Cesaro,2 Maurizio Aricò1 1Medical Department, Pediatric Unit, Azienda Sanitaria Provinciale Ragusa, Ragusa, 2Department of Pediatrics, Pediatric Hematology Oncology, Azienda Ospedaliera Universitaria Integrata, Verona, Italy Abstract: Advances in chemotherapy and surgery allows the majority of patients to survive cancer diseases. Yet, the price may be a proportion of patients dying of complications due to treatment-induced infectious complications, such as neutropenia. With the aim of decreasing morbidity and mortality related to infectious complications, recombinant human granulocyte colony-stimulating factor (G-CSF), filgrastim, and pegylated filgrastim have been used to reduce time and degree of neutropenia. A biosimilar is a copy of an approved original biologic medicine whose data protection has expired. The patent for filgrastim expired in Europe in 2006 and in the US in 2013. This review analyses the available evidence to be considered in order to design a strategy of use of G-CSF and its biosimilars. The clinical and safety outcomes of biosimilars are well within the range of historically reported data for originator filgrastim. This underscores the clinical effectiveness and safety of biosimilar filgrastim in daily clinical practice. Biosimilars can play an important role by offering the opportunity to reduce costs, thus contributing to the financial sustainability of treatment programs. Keywords: neutropenia, filgrastim, biosimilars, G-CSF, fever, prophylaxis
format	article
author	Caselli D Cesaro S Aricò M
author_facet	Caselli D Cesaro S Aricò M
author_sort	Caselli D
title	Biosimilars in the management of neutropenia: focus on filgrastim
title_short	Biosimilars in the management of neutropenia: focus on filgrastim
title_full	Biosimilars in the management of neutropenia: focus on filgrastim
title_fullStr	Biosimilars in the management of neutropenia: focus on filgrastim
title_full_unstemmed	Biosimilars in the management of neutropenia: focus on filgrastim
title_sort	biosimilars in the management of neutropenia: focus on filgrastim
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/4d89cc2f957e45c99acdc3cadddf2ed7
work_keys_str_mv	AT casellid biosimilarsinthemanagementofneutropeniafocusonfilgrastim AT cesaros biosimilarsinthemanagementofneutropeniafocusonfilgrastim AT aricom biosimilarsinthemanagementofneutropeniafocusonfilgrastim
_version_	1718401629205561344

Biosimilars in the management of neutropenia: focus on filgrastim

Ejemplares similares